Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450

Gene Therapy

Volumn 5, Issue 8, 1998, Pages 1070-1078

  Lohr M ^a   Muller P ^a   Karle, P ^b,c   Stange, J ^a   Mitzner, S ^a   Jesnowski, R ^a   Nizze, H ^d   Nebe, B ^a   Liebe, S ^a   Salmons, B ^a   Gunzburg W H ^b,c,d  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Bavarian Nordic GmbH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

Cytochrome P450; Encapsulation; Ifosfamide; Local therapy; Pancreatic cancer; Prodrug therapy

Indexed keywords

CELLULOSE SULFATE; CYTOCHROME P450; IFOSFAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; DRUG METABOLISM; ENCAPSULATION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMPLANTATION; INTRATUMORAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS;

ANIMALIA;

EID: 7344268645     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300671     Document Type: Article

References (37)

1. Chabot GG. Factors involved in clinical pharmacology variability in oncology. Anticancer Res 1994; 14: 2269-2272.
2. Benard J, Bourhis J , Riou G. Clinical significance of multiple drug resisitance in human cancers. Anticancer Res 1990; 10: 1297-1302.
3. Kobayashi H et al. Acquired rnulticelhilar-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 1993; 90: 3294-3298.
4. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997; 349: 485-489.
5. Abrams RA, Grochow LB. Adjuvant therapy with chemotherapy and radiation therapy in the managment of carcinoma of the pancreatic head. Surg Clin North Am 1995; 75: 925-938.
6. Howard TJ. Pancreatic adenocarcinoma. Curr Probl Cancer 1996; 20: 281-328.
7. Carmichael J et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-105.
8. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996; 78: 654-663.
9. Cerny T et al. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 1991; 117: S135-S138.
10. Keizer HJ et al. Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 1995; 121: 297-302.
11. Klapdor R et al. Determination of the tumour associated antigens CA 19-9 , CA 125 and CEA and the testing of drug sensitivity of gastrointestinal carcinomas transplanted to nude mice. In: Greten H, Klapdor R (eds). New Tumor-Associated Antigens. Georg Thieme: Stuttgart, 1986, pp 94-102.
12. Dirven H, van Ommen B, van Blaederen PJ. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol 1996; 9: 351-360.
13. Wei MX et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994; 5: 969-978.
14. Chen L, Waxman DJ. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581-589.
15. Elshami AA et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
16. Kloppel G, Lingenthal G, von Bulow M, Kern HF. Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases. Histopathology 1985; 9: 841-856.
17. Löhr M et al. Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins. Br J Cancer 1994; 69: 144-151.
18. Crandell RA, Fabricant CG, Nelson-Rees WA. Development, characterization, and virus susceptibility of a feline (Felis catus) renal cell line (CEFK). In Vitro 1973; 9: 176-185.
19. Donato MT, Gomez-Lechon MJ, Castell JV. A microassay for measuring cytochrome P450IA1 and P450IIBI activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 1993; 213: 29-33.
20. Wright JE et al. Analysis of 4-hydroxycyclophosphamide in human blood. Analyt Biochem 1995; 224: 154-158.
21. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
22. Lieber M et al. Establishment of a continuous tumor-cell line (PANC1) from a human carcinoma of the exocrine pancreas. Int J Cancer 1975; 15: 741-747.
23. Stange J et al. Prolonged biochemical and morphological stability of encapsulated liver cells - a new method. Biomat Art Cells Immob Biotech 1993; 21: 343-352.
24. Sladek NE, Powers JF, Grage GM. Half-life of oxazaphosphorines in biological fluids. Drag Metab Dispos 1984; 12: 553-559.
25. Morris PJ. Immunoprotection of therapeutic cell transplants by encapsulation. Trends Biotech 1996; 14: 163-167.
26. Formela LJ, Galloway SW, Kingsnorth AN. Inflammatory mediators in acute pancreatitis. Br J Surg 1995; 82: 6-13.
27. Raper SE DeMatteo RP. Adenovirus-mediated in vivo gene transfer and expression in normal rat pancreas. Pancreas 1996; 12: 401-410.
28. Chen L, Waxman DJ, Chen D, Kufe DW. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996; 56: 1331-1340.
29. Kedzie KM et al. Molecular basis for a functionally unique cytochrome P450UB1 variant. J Biol Chem 1991; 266: 22515-22521.
30. Fuji-Kuriyama Y et al. Primary strucuture of a cytochrome P450: coding nucleotide sequence of phenobarbital-inducible cytochrome P-450 cDNA from rat liver. Proc Natl Acad Sci USA 1982; 79: 2793-2797.
31. Reyes G et al. Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. Cancer Res 1996; 56: 5713-5719.
32. Kalthoff H et al. Modulation of platelet-derived growth factor A- and B-chain/c-sis mRNA by rumor necrosis factor and other agents in adenocarcinoma cells. Oncogene 1991; 6: 1015-1021.
33. Löhr M et al. Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. Pancreas 1996; 12: 248-259.
34. Schmiegel W et al. Tumor necrosis factor a and the epithelial growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci USA 1993; 90: 863-867.
35. WHO. Handbook for Reporting Results of Cancer Treatment. 1979. References added in proof
36. Saller RM, Günzburg WH, Salmons B. Microcapsules provide a novel alternative for systemic virus release; retrovirus vector slow release from packaging cell culture in a mouse gene therapy model. Gene Therapy 1995; 2 (Suppl. 1): S12.
37. Saller RM et al. Encapsulated cells producing retroviral vectors for in vivo gene therapy (submitted).